» Articles » PMID: 9649961

Investigation of Hallucinogenic and Related Beta-carbolines

Overview
Publisher Elsevier
Specialty Psychiatry
Date 1998 Jul 3
PMID 9649961
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Certain beta-carbolines are known to be hallucinogenic in humans, and several produce stimulus effects in animals similar to those of the classical hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM). Classical hallucinogens bind at 5-HT2 serotonin receptors and these receptors are thought to play a role in their mechanism of action. In the present study, we examined the binding of 15 beta-carbolines at rat 5-HT2A and 5-HT2C receptors. Affinities (Ki values) of the beta-carbolines ranged from about 100 nM to greater than 10,000 nM depending upon the degree of saturation of the pyridyl ring, and upon the presence and location of methoxy substituents in the benzenoid ring. In a further study, six rats were trained to discriminate the hallucinogenic beta-carboline harmaline (3.0 mg/kg, i.p.) from vehicle using a VI-15s schedule of reinforcement. This represents the first time a hallucinogenic beta-carboline has been used as a training drug in a drug discrimination study. Administration of DOM to the harmaline-trained animals resulted in 76% harmaline-appropriate responding at 1.25 mg/kg DOM and disruption of behavior at a higher dose. Taken together, the results of the present investigation demonstrate that: (a) certain beta-carbolines bind at 5-HT2 receptors; (b) that harmaline serves as a training drug at 3.0 mg/kg in drug discrimination studies with rats as subjects; and that (c) there is some similarity between the stimulus effects produced by harmaline and DOM.

Citing Articles

Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.

Egger K, Aicher H, Cumming P, Scheidegger M Cell Mol Life Sci. 2024; 81(1):395.

PMID: 39254764 PMC: 11387584. DOI: 10.1007/s00018-024-05353-6.


Cortical structural differences following repeated ayahuasca use hold molecular signatures.

Mallaroni P, Mason N, Kloft L, Reckweg J, van Oorsouw K, Ramaekers J Front Neurosci. 2023; 17:1217079.

PMID: 37869513 PMC: 10585114. DOI: 10.3389/fnins.2023.1217079.


Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant.

Rossi G, Guerra L, Baker G, Dursun S, Saiz J, Hallak J Biomolecules. 2022; 12(11).

PMID: 36358968 PMC: 9687782. DOI: 10.3390/biom12111618.


Computational Insights into β-Carboline Inhibition of Monoamine Oxidase A.

Prah A, Gavranic T, Perdih A, Dolenc M, Mavri J Molecules. 2022; 27(19).

PMID: 36235246 PMC: 9571839. DOI: 10.3390/molecules27196711.


Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil.

Daldegan-Bueno D, Maia L, Massarentti C, Tofoli L Psychopharmacology (Berl). 2022; 239(6):1767-1782.

PMID: 35179623 DOI: 10.1007/s00213-022-06063-2.